Joshua D E, Wearne A, Kronenberg H
Lancet. 1987 Jan 31;1(8527):251-3. doi: 10.1016/s0140-6736(87)90067-5.
In patients in the plateau phase of myeloma, expression of the light-chain isotype concordant with the malignant paraprotein on peripheral-blood lymphocytes is suppressed. This light-chain-isotype suppression (LCIS) is lost when the disease becomes progressive. LCIS is identified by quantifying kappa and lambda cells in peripheral blood in an indirect immunofluorescence assay. In 27 patients presenting with myeloma, the prognosis was significantly better for patients with LCIS at presentation than for those without. Bone-marrow mononuclear cells, studied in 7 patients with myeloma and LCIS in peripheral blood, did not show LCIS.
在处于骨髓瘤平台期的患者中，外周血淋巴细胞上与恶性副蛋白相一致的轻链同种型的表达受到抑制。当疾病进展时，这种轻链同种型抑制（LCIS）消失。通过间接免疫荧光测定法对外周血中的κ和λ细胞进行定量来识别LCIS。在27例骨髓瘤患者中，出现LCIS的患者的预后明显好于未出现LCIS的患者。对7例外周血中有骨髓瘤和LCIS的患者的骨髓单个核细胞进行研究，未发现LCIS。
